IU School of Medicine researchers to present respi newswise.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswise.com Daily Mail and Mail on Sunday newspapers.
Date Time
Share
Case Western Reserve and Atelerix Life Sciences Inc. sign option license to develop new therapeutic approach to opioid crisis
Novel small molecule technology reverses life-threatening opioid-induced respiratory depression without diminishing pain relief
Case Western Reserve University and Atelerix Life Sciences Inc., a Charlottesville, Virginia-based biotechnology company, have signed a two-year option to license a novel family of small molecules called Active Thiol-Based Compounds (ATBC’s) to prevent or reverse life-threatening opioid-related side effects.
The lead compound, ATLX-0199 (also called sudaxine), will be first targeted at opioid-induced respiratory depression (OIRD) in the hospital setting.
A recent study by the medical technology company Medtronic found that 46% of surgical patients receiving opioids for post-operative pain-relief suffer one or more episodes of OIRD, presenting perhaps the most significant obstacle to discharge from intensive ca
CWRU, Atelerix sign option license to develop therapeutic approach to opioid crisis
CWRU, Atelerix sign option license to develop therapeutic approach to opioid crisis
Print
Case Western Reserve University and Atelerix Life Sciences Inc., a Charlottesville, Va.-based biotechnology company, have signed a two-year option to license novel, small-molecule technology to prevent or reverse life-threatening opioid-related side effects, according to a news release.
A recent study by medical technology company Medtronic found that 46% of surgical patients receiving opioids for post-operative pain relief suffer one or more episodes of opioid-induced respiratory depression (OIRD), presenting a significant obstacle to discharging patients from intensive care units and the hospital, the release stated.